Medical device producer Oscor has led the heart disease treatment system developer's $20m series D round in connection with a strategic partnership.
Micro Interventional Devices (MID), a US-based developer of heart disease treatment systems, has completed a $20m series D round led by medical device maker Oscor.
Originate Ventures, LifeSciences Greenhouse of Central Pennsylvania and Ben Franklin Venture Partners also contributed to the round, as did undisclosed existing shareholders. Oscor CEO Thomas Osypka is joining MID’s board of directors in connection with the round.
MID has developed devices that allow surgeons to perform minimally invasive procedures such as mitral valve repair and…
